The FDA's Office of Oncology Products has come in for stinging criticism from drug developers, advocates and even a US legislator over the use of surrogate endpoints. Has the agency struck the right balance between speed and caution? Malorye Allison investigates.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Allison, M. Trouble at the office. Nat Biotechnol 26, 967–969 (2008). https://doi.org/10.1038/nbt0908-967
Issue Date:
DOI: https://doi.org/10.1038/nbt0908-967
- Springer Nature America, Inc.
This article is cited by
-
The cancer vaccine roller coaster
Nature Biotechnology (2009)
-
Fresh from the biologic pipeline
Nature Biotechnology (2009)